Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy

STRATUM I INCLUSION:

Each patient must have a proven pathologic diagnosis of solid tumor; the tumor must be refractory to conventional therapies, or for which no effective therapy is known; patients with brain tumors are eligible, but they should not be receiving anticonvulsants; the requirement for histologic diagnosis can be waived for patients with brainstem gliomas

Karnofsky \>= 50% for patients \> 10 years of age; Lansky play scale \>= 50% for children =\< 10 years of age; neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 2 weeks prior to study entry; patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score

Life expectancy \>= 8 weeks

Nutrition status \>= 3rd percentile weight for height and serum albumin \>= 2.5 g%

Prior therapy: patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, and must be without significant systemic illness (e.g., infection, fever, mucositis, severe anorexia, and severe malnutrition)

* Myelosuppressive chemotherapy must not have been received within 3 weeks of entry on this study (six weeks if a prior nitrosourea)

* Biologic, anti-neoplastic agents must not have received at least 1 week

* Radiation \>= 2 weeks must have been elapsed from prior local radiation (small port); \>= 6 months must have been elapsed from prior craniospinal radiation or \>= 50% radiation of the pelvis; 6 weeks must have been elapsed from substantial bone marrow radiation

* Autologous or allogeneic BMT without TBI \>= 6 months must have been elapsed, with no evidence of GVH disease

Growth factor(s) must not have been received within one week of entry on this study

Steroids: patients with CNS tumors who are receiving dexamethasone must be on a stable or decreasing dose for at least 2 weeks prior to study entry

ANC \>= 1,000/ul

Hemoglobin \>= 8.0 g/dL

Platelet count \>= 100,000/ul

Bilirubin =\< 1.5 mg/dL

SGPT =\< 2 times upper limit of normal

Albumin \>= 2.5 g/dL

Normal serum creatinine for age or, if abnormal serum creatinine, normal GFR for age

All patients (or their legal guardians if patient is less than 18 years of age) must sign a document of informed consent that has been approved by the Institutional Human Review Committee; when appropriate the patient will be included in all discussions in order to obtain verbal assent

The Phase I Office must give permission to register the patient; registration must occur on the day the patient receives the treatment; however, the registration should precede the drug administration

Protocol must be approved by the local Institutional Review Board (IRB) prior to any patient registration and reapproved every twelve months

What this study is about